The Ace2p and Swi5p zinc finger proteins have nearly identical DNA-binding domains, yet in vivo they activate transcription of different genes, CTS1 and HO. We now demonstrate that Ace2p and Swi5p recognize sites in the CTS1 and HO promoters with the same affinities, raising the question of how promoter specificity is achieved by these proteins with similar DNA-binding domains. It has been previously shown that Swi5p binds to the HO promoter cooperatively with the Pho2p (Bas2p/Grf10p) homeodomain protein, and we now show that Ace2p does not interact with Pho2p. Analysis of CTS1 promoter fragments inserted into a heterologous promoter identify a sequence 90 bp away from the Ace2p binding sites which is required to prevent activation by Swi5p through these binding sites. These results suggest that a regulatory protein bound to the CTS1 promoter is needed to prevent Swi5p from activating CTS1 expression. A genetic screen was conducted to identify suppressor mutations which allow CTS1 expression in the absence of the Ace2p activator. The nce3 mutation suppresses the ace2 defect in CTS1 expression only if the strain contains a functional SWI5 gene, suggesting that NCE3 normally functions to prevent Swi5p from activating CTS1. The role of negative regulators such as NCE3, as well as the previously described SIN5 gene, in determining the promoter specificity of homologous activators is discussed.
used to disrupt the SWI5 and CTS1 genes with a hisG-URA3-hisG allele (1) , and then the strains bearing the swi5::hisG-URA3-hisG or cts1::hisG-URA3-hisG allele were passaged over 5-fluoro-orotic acid medium (3) to select for loss of the URA3 marker, resulting in strains with a swi5::hisG or a cts1::hisG allele. Similarly, plasmid pNKY85 (1) was used to convert the pho2::LEU2 allele to a pho2::hisG allele. Gene disruptions were confirmed by Southern blotting. Media and cell cultivation conditions are indicated in the text or as described previously (20, 21) . Cells were grown at 30ЊC in synthetic complete medium (35) containing 2% glucose supplemented with adenine, uracil, and amino acids, as appropriate, but lacking essential components to select for plasmids. YEPD and 5-fluoroorotic acid media and plates were prepared as described (35, 37) .
Ethyl methanesulfonate mutagenesis (26) of strains DY2051 and DY2052 was performed under conditions that yielded a survival rate of 60%. Mutagenized cells were plated onto nitrocellulose filters resting on YEPD plates, and colonies were screened for lacZ activity on 5-bromo-4-choro-3-indolyl-␤-D-galactopyranoside (X-Gal) after freezing in liquid nitrogen. From 40,000 colonies screened, 84 blue colonies were identified after 45 to 90 min of incubation with X-Gal at room temperature. The number of potential mutants was reduced to 28 by rescreening, and 3 mutants showed a dominant phenotype when mated to an NCE ϩ parent. Complementation analysis demonstrated that there were three alleles for nce1, two alleles for nce2, and two alleles for nce3. Complementation analysis of the remaining 18 mutants is still in progress.
Plasmids. Table 2 lists all plasmids used. In many cases, multiple steps were involved in plasmid construction, and details are available upon request. Plasmid M596, containing a swi5::hisG-URA3-hisG allele, was constructed by replacing the BglII (Ϫ875 to ϩ1702) fragment in SWI5 cloned in pUC19 with a 3.8 kb BamHI-BglII fragment of pNKY51 (1) . Similarly, the BglII fragment (Ϫ177 to ϩ2032) of CTS1 was deleted in the construction of plasmid M1475, containing a cts1::hisG-URA3-hisG allele. Plasmid M1225 was designed for gamma disruption (38) of ACE2, deleting sequences from the BglII site to the KpnI site (ϩ212 to ϩ1764), and is derived from plasmid pRS304 (38) .
Plasmid M1659 contains a 3.5-kb BamHI-EcoRI fragment with CTS1 subcloned into pTF63 (29) . The CTS1-lacZ reporter plasmid M1591 (URA3 marker) is derived from YEp353 (30) and contains 1.4 kb of the CTS1 promoter driving expression of the lacZ gene.
The CTS1-CYC1-lacZ reporters listed in Table 2 contain CTS1 promoter fragments inserted upstream of the CYC1 TATA element in plasmid pLG⌬-178 (17) or a derivative with additional restriction sites. M2570 is identical to M1820, in which the CTS1 promoter region from Ϫ651 to Ϫ394 is driving expression of CTS1-lacZ, except that an XhoI site was introduced between the two Ace2p binding sites by changing two nucleotides by site-directed mutagenesis as described below. Plasmids M2337 and M3121 contain CTS1 promoter fragments inserted between the CYC1 upstream activation sequence (UAS) and TATA elements in plasmid pLG⌬-312 (16) .
Bacterial expression plasmids M1462 and M1642 direct expression of glutathione S-transferase (GST)-Ace2p (amino acids 491 to 771) and GST-Swi5p (amino acids 384 to 709) fusion proteins, respectively. These plasmids are derived from pGEX-3X (Pharmacia), and bacterial expression is under control of the tac promoter. Plasmid M2025 (5) expresses His-tagged Pho2p from plasmid pET21b (Novagen). Plasmid M1402 (CS169 [4] ) contains the Swi5p and Pho2p binding sites from the HO promoter in pIC19R. Plasmid M1818 contains a CTS1 promoter fragment from Ϫ651 to Ϫ394, including the two Ace2p binding sites, cloned into pIC19H.
Plasmid YCpALTER-URA3 (M2437) was constructed by replacing the 1.47-kb PvuI fragment of pALTER-1 (Promega) with the 2.97-kb PvuI fragment from pRS316 (38) , which contains a centromere, an autonomously replicating sequence, and the URA3 gene. pALTER-1 is designed for efficient site-directed mutagenesis, and the YCpALTER-URA3 derivative is a yeast shuttle vector. Plasmid M2457, which was used for random mutagenesis of a region of the CTS1 promoter, was constructed in two steps. First, a 4.68-kb BamHI-NsiI CTS1-lacZ fragment from M1591 was inserted into YCpALTER-URA3 that had been digested partially with PstI and to completion with BamHI, and then an XhoI site was introduced between the two Ace2p binding sites by changing two nucleotides by site-directed mutagenesis with oligonucleotide F230 (5Ј ATGCTGGTCCCTc GAgAAAATAACCAGC 3Ј) and the Altered Sites mutagenesis kit (Promega).
Directed mutagenesis of the negative regulatory region. The following oligomer was designed to introduce mutations in the negative regulatory site at the CTS1 promoter: 5Ј-GTGTTTGTTTATTTGTTTATGTGTTTCAGATGTTGAG TAAACATTAGCATTGGTGTAAGAA-3Ј. The letters in boldface indicate residues in the sequence that were doped with other nucleotides at a concentration of 8.1%, which should yield an average of three mutations per oligonucleotides (18, 27) .
Site-directed mutagenesis was performed according to the instructions for the Promega Altered Sites mutagenesis kit, with the following exceptions. After annealing of both the ampicillin repair oligomer and the mutagenic oligomer, T4 gene 32 protein (Pharmacia) or single-stranded binding protein was added at a final concentration of 0.2 g/l. The gene 32 protein was added to prevent annealing within the inverted repeat formed by lacZ in the CTS1-lacZ reporter and the lacZЈ in the vector, thus reducing the formation of deletions by increasing the fidelity of the subsequent synthesis reaction. After a 5-min incubation at room temperature, the microcentrifuge tube was placed on ice for 5 min to stimulate the binding of the gene 32 protein. The components of the synthesis reaction were then added to the reaction mixture on ice. Escherichia coli BMH71-18 mutS (Promega) was made competent by the procedure of Chung and Miller (10) on the day of the mutagenesis experiment. DNA was prepared from this strain by a Triton lysis procedure (2) .
In vitro binding assays. Gel retardation assays were performed as described previously (4) . All binding reaction mixtures (20-l volume) used in gel retardation experiments contained the following components: 15 mM Tris (pH 8.0), 75 mM NaCl, 750 g of bovine serum albumin (Sigma) per ml, 12.5 mM dithiothreitol, 7.5% glycerol, 50 g of poly(dI-dC) ⅐ poly(dI-dC) per ml, and approximately 1 ng of labeled probe (about 30,000 cpm). The same binding conditions for gel retardation assays were used for DNase I footprint analysis except that reaction volumes were doubled (40 l) and did not contain poly(dIdC) ⅐ poly(dI-dC).
End labeling of the 258-bp CTS1 promoter fragment (Ϫ651 to Ϫ394 and containing both Ace2p binding sites) at either the BamHI or the EcoRI site of M1818 was followed by digestion with the other restriction enzyme. End labeling of the HO site B probe at either the HindIII or the Asp 718 site of M1402 was followed by digestion with the other restriction enzyme. All probes were end labeled with T4 polynucleotide kinase and [␥- 32 P]ATP (9,000 Ci/mmol). The GST-Ace2 and GST-Swi5 fusion proteins were purified as described previously (4) except for the following changes. Upon addition of isopropyl-␤-D-thiogalactoside (IPTG) to induce fusion protein expression, Zn(C 2 H 3 O 2 ) 2 ⅐ 2H 2 O was added to the culture at a final concentration of 0.1 mM. Sodium dodecyl sulfate-gel electrophoresis demonstrated that the concentrations of the purified GST-Ace2 and GST-Swi5 fusion proteins are equivalent (data not shown). The Pho2-HIS fusion protein was purified as described previously (4) . The purified proteins were not subjected to a secondary DNA affinity purification step. The purified proteins were dialyzed against AN100 buffer (4) .
Miscellaneous methods. Primer extension analysis was performed essentially as described previously (43) . The CTS1 (5Ј-TTCCTGCTGAGTTTTGACCC-3Ј) and URA3 (5Ј-CGTGCATGATATTAAATAGC-3Ј) primer oligonucleotides were labeled with [␥- VOL. 16, 1996 NEGATIVE REGULATION AT CTS1 1747 transcriptase. The primer extension products were electrophoretically separated on a 14.5-cm 6% polyacrylamide-8 M urea gel and autoradiographed. Northern (RNA) analysis was performed as described previously (14) . lacZ color colony assays were performed by the procedure of Breeden and Nasmyth (6), using 8.26-cm-diameter Whatman grade 5 filters instead of nitrocellulose. Quantitative ␤-galactosidase activity assays were performed as described previously (7). Computer-generated images of autoradiographs were generated with Adobe Photoshop.
RESULTS

CTS1
promoter. We demonstrated previously that ACE2 functions as a transcriptional regulator of the CTS1 gene (14) . The published sequence upstream of the CTS1 gene (24) , extending 450 bp upstream of the initiating methionine codon, did not contain any sequence homologous to the Swi5p binding site in the HO promoter. We therefore isolated a clone which includes DNA extending approximately 1,400 bp upstream of CTS1, constructed exonuclease III deletions, and determined the DNA sequence of this region. As shown in Fig. 1 , there is an upstream open reading frame, and thus the CTS1 promoter region can extend as far as Ϫ856. The promoter contains several potential Ace2p binding sites, which are indicated in Fig. 1 . These potential binding sites contain a characteristic ACCAGC or the complementary GCTGGT sequence which is found in the core of the site B Swi5p binding site in the HO promoter (see below). While this report was in preparation, the sequence of this region from chromosome XII was submitted to GenBank (accession number U17243) as part of the yeast genome sequencing project. The two sequences are identical.
The exonuclease III deletion clones generated for sequencing were used in a complementation experiment to identify promoter regions required for normal regulation of the CTS1 gene. In this experiment, promoter deletion clones were transformed into strain DY1595, which contains a CTS1 gene deletion. RNA was isolated from logarithmically growing cells, and CTS1 mRNA levels were determined by primer extension analysis (Fig. 2) . A control primer extension experiment was also conducted with a URA3-specific primer, and the results show that the RNA is not degraded in any of the samples (data not shown). The major transcription start site is located at Ϫ238 Ϯ 10 bp from the ATG, and thus CTS1 has a rather long 5Ј untranslated region by yeast standards. A perfect TATAAA element is present 70 bp upstream of the transcription start site. The primer extension analysis demonstrates that clones extending 1396, 1067, or 687 bp upstream of the ATG promoter direct full CTS1 expression (Fig. 2, lanes 4 to 6) . In contrast, a clone which contains sequences 525 bp upstream of the ATG showed a reduced level of the normal primer extension product, and some transcripts were longer, indicating abnormal start site selection (lane 7). Importantly, all but one of the potential Ace2p binding sites have been deleted in this promoter construct. Finally, clones deleted to 122 bp upstream 9) , as expected, since these clones lack the transcription start site. On the basis of the primer extension data, the sequences sufficient for normal expression of a plasmid-borne CTS1 promoter are located within the 687-bp region upstream of the ATG. Binding sites for Ace2p and Swi5p. We predicted that Ace2p and Swi5p should recognize the same DNA sequences (14) , given the strong similarity of their DNA-binding domains. We have studied the binding of Swi5p to the HO promoter (site B) in some detail, using DNase I footprinting, methylation interference, and hydroxyl radical interference methods (4, 5) . A summary of these contacts between Swi5p and the HO promoters site is shown in Fig. 3 . The core of this binding site, ACCAGC, is present three times in the CTS1 promoter (indicated in Fig. 1) . Two of the three potential Ace2p binding sites from the CTS1 promoter demonstrated a strong similarity to the site B Swi5p binding site at the HO promoter (Fig. 3) . The left binding site or CTS1 site L shows a 10-of-16-nucleotide (nt) match with the Swi5p binding site, while the right hand binding site or CTS1 Site R shows a remarkable 14-of-16 match.
Given the similarity of the Swi5p binding site at the HO promoter with the potential Ace2p binding sites at the CTS1 promoter and given the similarity of the DNA-binding domains of the Ace2p and Swi5p activators, we decided to test the hypothesis that both proteins would bind to the same sequences in vitro. Ace2p and Swi5p were expressed in E. coli as GST fusion proteins and purified by using a glutathioneagarose affinity resin. In the GST-Ace2p construct, the GST domain was fused to the carboxy-terminal 281 amino acids of Ace2p, which contains the proposed zinc finger DNA-binding Primer extension analysis of CTS1 promoter deletion constructs. A map of the different CTS1 deletion constructs, and the Ace2p binding sites, is presented at the top. Yeast strain DY1595, containing a cts1⌬::hisG gene disruption, was transformed with the indicated CTS1 deletion construct. Transformants were grown under selective conditions to maintain the plasmid, and RNA isolated from log-phase cells was used for primer extension reactions with a CTS1-specific primer (lanes 4 to 9). Control reactions were also performed with tRNA (lane 1), with mRNA isolated from a cts1⌬::hisG strain not bearing any plasmid (lane 2), and with mRNA isolated from a cts1⌬::hisG strain bearing the parental vector pTF63 (lane 3). The major primer extension product is indicated. A control primer extension experiment was also conducted with a URA3-specific primer, and the results show that the RNA is not degraded in any of the samples (data not shown).
VOL. 16, 1996 NEGATIVE REGULATION AT CTS1domain, while the GST-Swi5p construct contained GST fused to the carboxy-terminal 326 amino acids of Swi5p. Attempts to express the full-length coding region of Ace2p (770 amino acids) in E. coli were unsuccessful because of proteolysis in the bacterial strain (data not shown). Gel shift analysis was first performed with a labeled DNA fragment bearing Swi5p binding site site B from the HO promoter plus either the Ace2 or the Swi5 fusion protein (Fig. 4A , lanes 2 to 5 and 11 to 14). Incubation of either GST-Ace2p or GST-Swi5p with HO DNA results in a more slowly migrating protein-DNA complex. Moreover, the binding affinities of the two proteins appear to be the same. We conclude that GST-Ace2p and GST-Swi5p bind to the HO promoter with similar affinities. To determine whether Ace2p or Swi5p can bind to the CTS1 promoter, a 258-bp CTS1 promoter fragment was used in gel shift and DNase I footprinting experiments. The gel shift analysis shown in Fig. 4B (lanes 2 to 5 and 11 to 14) shows that two types of protein-DNA complexes result from binding of either GST-Ace2p or GST-Swi5p. The first, faster-migrating species appeared at lower protein concentrations. The more slowly migrating species appeared at much higher protein concentrations, indicating that either fusion protein can bind to two sites in the CTS1 promoter. It appears that formation of a ternary complex containing two protein molecules bound to DNA is not cooperative (Fig. 4B and data not shown). The DNase I footprinting experiment shown in Fig. 5 demonstrates that GST-Ace2p or GST-Swi5p protects two distinct regions of the CTS1 promoter from DNase I cleavage. Two conclusions can be drawn from this footprinting experiment. First, Ace2p and Swi5p recognize the same CTS1 DNA sequences in vitro. Second, the regions of the CTS1 promoter that are recognized by Ace2p and Swi5p correspond to CTS1 site L and CTS1 site R, which show homology to the Swi5p binding site in the HO promoter. Both regions of protection contain the ACCAGC core found at the HO promoter. In summary, we conclude that the CTS1 promoter contains two binding sites for either GSTAce2p or GST-Swi5p and that the affinities of these two proteins for the CTS1 promoter are similar.
ACE2 and SWI5 regulate distinct genes in vivo (14) . ACE2 activates the CTS1 gene, whereas SWI5 activates HO. However, given that Ace2p and Swi5p can bind to the same sequences in vitro, it is not clear why these transcription factors activate distinct genes. Thus, we undertook experiments to examine the mechanism of selective activation of CTS1 by Ace2p.
Ace2p does not bind cooperatively with Pho2p. The binding specificity of a transcriptional activator for a particular promoter can be enhanced by the presence of additional protein factor(s). We have demonstrated that Swi5p binds cooperatively to the HO promoter with the Pho2p homeodomain protein (4, 5) . Pho2p increases the affinity of Swi5p for the HO promoter, and thus it is possible that interaction with Pho2p plays a role in the specific activation of HO by SWI5 but not by ACE2. To address this question, we performed biochemical and genetic experiments to determine whether Ace2p can in- (A) A gel shift assay was performed with a radioactively labeled HO promoter fragment containing Swi5 binding site B from plasmid pM1402 and with purified GST-Ace2p, GST-Swi5p, and Pho2p. The positions in the gel corresponding to the binary protein-DNA complex (single protein bound), the ternary protein-DNA complex (two proteins bound), and the free HO probe are indicated. (B) A gel shift assay was performed with a radioactively labeled CTS1 promoter fragment containing the CTS1 Ϫ651 to Ϫ394 promoter probe from plasmid pM1818 and with purified GST-Ace2p, GST-Swi5p, and Pho2p. The positions in the gel corresponding to the binary protein-DNA complex (single protein bound), the ternary protein-DNA complex (two proteins bound), the quaternary protein-DNA complex (three proteins bound), and the free CTS1 probe are indicated. The binding reactions in each panel were the same (except for the labeled DNA probe), as follows: no protein added (lane 1); GST-Ace2p, 1 l (lanes 2 and 7), 2 l (lanes 3 and 8) 3 l (lanes 4 and 9), and 4 l (lanes 5 and 10); GST-Swi5p, 1 l (lanes 11 and 16), 2 l (lanes 12 and 17), 3 l (lanes 13 and 18), and 4 l (lanes 14 and 19); Pho2p, 4 l (lanes 6 to 10 and 15 to 19). A lacZ reporter plasmid driven by 1.4 kb of the CTS1 promoter was used to determine whether PHO2 is required for CTS1 expression. This CTS1-lacZ reporter plasmid was transformed into eight isogenic strains that differ only at the ACE2, SWI5, and PHO2 loci. Transformants were grown under selection to maintain the CTS1-lacZ reporter plasmid, and extracts were prepared from log-phase cells for quantitative ␤-galactosidase measurements. The results in Table 3 confirm that CTS1 expression requires ACE2 but not SWI5. Importantly, a pho2 mutation does not lead to a reduction in CTS1 expression in any of the four genotypes tested.
Gel shift experiments were performed with purified GSTAce2p and GST-Swi5p in the absence or presence of added Pho2p. A labeled DNA probe containing sequences from the HO promoter was used for the experiment shown in Fig. 4A . The cooperative binding of Swi5p and Pho2p at HO can be seen by comparing Swi5p binding in the absence (lanes 11 to 14) and presence (lanes 16 to 19) of Pho2p. Pho2p addition results in the conversion of the Swi5p-DNA binary complex into the more slowly migrating Swi5p-Pho2p-DNA ternary complex. Similarly, the Pho2p-DNA binary complex (lane 15) disappears upon addition of Swi5p (lanes 16 to 19). In contrast, addition of Pho2p (lanes 7 to 10) causes no apparent increase in affinity of Ace2p for the HO promoter compared with Ace2p alone (lanes 2 to 5). Both Pho2p and Ace2p can bind to the HO promoter, but no ternary complexes containing both proteins can be seen, suggesting that binding by both Ace2p and Pho2p is independent and not cooperative.
The analogous gel shift experiment performed with a CTS1 promoter probe is shown in Fig. 4B . First, Pho2p does bind to the CTS1 promoter fragment (lanes 6 and 15). In vitro binding by homeodomain proteins shows low sequence selectivity (25) , with the common sequence TAAT being a primary binding determinant. We suggest that the in vitro binding of Pho2p to CTS1 results from this type of low selectivity (TAAT motifs are present in the CTS1 probe), since CTS1 expression is not reduced by a pho2 mutation (Table 3) .
Comparison of Ace2p binding in the absence (Fig. 4 , lanes 2 to 5) and presence (lanes 7 to 10) of Pho2p demonstrates that Pho2p does not enhance the affinity of Ace2p for the CTS1 promoter. Moreover, there is no evidence for a protein-DNA complex that contains both Ace2p and Pho2p. Different results were obtained when Swi5p binding to the CTS1 promoter was measured in the absence (lanes 11 to 14) and presence (lanes 16 to 19) of added Pho2p. First, incubation of both Swi5p and Pho2p (lanes 16 to 19) results in a sharp increase in the amount of ternary complex and the appearance of an additional species (quaternary complex) which may contain DNA bound by two molecules of Swi5p and one molecule of Pho2p. Second, the amount of the Pho2p-DNA binary complex (lane 15) decreases upon addition of Swi5p (lanes 16 to 19) . However, the Swi5p-dependent decrease in the Pho2p-DNA binary complex with the CTS1 probe (Fig. 4B, lanes 15 to 19) is slight compared with the highly cooperative interactions seen at the HO promoter (Fig. 4A, lanes 15 to 19) .
The analysis of binding at CTS1 is complicated by several features. First, since the CTS1 probe contains two binding sites for Ace2p or Swi5p, it is not clear if a more slowly migrating ternary complex (Fig. 4B, lanes 15 to 19) contains two molecules of Swi5p or one molecule of Swi5p and one molecule of Pho2p. Second, because the Swi5p-DNA and the Pho2p-DNA binary complexes run with the same mobility on the CTS1 promoter, the disappearance of the Pho2p-DNA complex is difficult to monitor. Nevertheless, these results demonstrate that the interaction of Swi5p with Pho2p is specific because Ace2p fails to interact with Pho2p.
The in vitro DNA-binding experiments suggested that Swi5p and Pho2p may interact at the CTS1 promoter. To determine whether this observation had any relevance for regulation in vivo, genetic experiments using a CTS1-lacZ reporter were performed. Although CTS1 expression is normally independent of SWI5 (14) , SWI5 overexpression promotes expression of CTS1 in an ace2 mutant (14) . We reasoned that if Pho2p is required for efficient Swi5p binding to the CTS1 promoter in vivo, then a pho2 mutation should abrogate the ability of overexpressed Swi5 to activate CTS1. However, suppression of the ace2 defect in CTS1 expression by SWI5 overexpression does not require PHO2 (data not shown). This finding indicates that in vivo binding of Swi5p to the CTS1 promoter does not require Pho2p. Similarly, ACE2 overexpression can suppress a swi5 defect in HO expression (14) , and this ACE2 suppression is independent of PHO2 (data not shown). We conclude that the ACE2 suppression of the swi5 defect at HO does not require PHO2.
In summary, the in vitro DNA-binding experiments demon- Identification of a UAS within the CTS1 promoter. To demonstrate in vivo that ACE2 activates CTS1 transcription through the binding sites mapped by sequencing and DNAbinding experiments, analysis of the CTS1 cis-acting promoter sequences in a heterologous context was undertaken. Plasmid pLG⌬178 contains the CYC1 TATA box fused to the lacZ gene but lacks a UAS, and thus this promoter is transcriptionally inactive (17) . A fragment containing a UAS can be inserted into this vector, and the resulting transcriptional activity can be measured quantitatively by performing ␤-galactosidase assays. A 258-bp fragment extending from nt Ϫ651 to Ϫ394 of the CTS1 promoter, which binds Ace2p in gel shift assays (Fig. 5) , was cloned into pLG⌬178 to test it for UAS activity. As shown in Table 4 , the 258-bp fragment in plasmid CTS1(258)-CYC1-lacZ contained UAS activity, exhibiting 3,200 U of ␤-galactosidase activity in a wild-type strain. As a control, the pLG⌬178 vector, which lacks a UAS, showed less than 10 U of ␤-galactosidase activity. The CTS1(258)-CYC1-lacZ plasmid was subsequently transformed into a series of isogenic strains bearing null alleles of ACE2 and/or SWI5 (Table 4) . When the ␤-galactosidase levels were measured from either the ace2 single or the ace2 swi5 double mutant, the level of activity dropped to 1% of the wild-type level. On the other hand, the level of ␤-galactosidase activity in a swi5 single mutant was close to normal, at 70% of wild-type activity. Thus, one can conclude that the region of the CTS1 promoter extending from nt Ϫ651 to Ϫ394 contains a UAS which is dependent on the presence of ACE2, but not SWI5, for activation. Sequences from the CTS1 promoter downstream of Ϫ394, when cloned into pLG⌬178, failed to demonstrate any UAS activity (data not shown).
For comparison, plasmid YEpCTS1-lacZ, bearing the fulllength promoter (including the CTS1 TATA box) driving expression of the lacZ reporter gene, was transformed into the same isogenic four strains. Although the level of activation from the full-length promoter is significantly higher than that from the CTS1(258)-CYC1-lacZ construct (13,000 U, compared with 3,200), the normalized levels of activation show a profile similar to that of the 258-bp construct. The level of activation from the YEpCTS1-lacZ reporter is significantly reduced in the ace2 single-mutant and the ace2 swi5 doublemutant strains. We attribute the increased level of activation in the YEpCTS1-lacZ construct to sequences extending beyond the 258-bp fragment. Additionally, these experiments show that CTS1 is a very strong promoter, as these ␤-galactosidase levels are very high compared with those for other lacZ promoter fusions or other CYC1-lacZ promoter constructs.
A 46-bp fragment from the CTS1 promoter demonstrates UAS activity. The DNase I footprinting experiments identified two high-affinity binding sites for Ace2p within the 258-bp CTS1 DNA promoter fragment. On the basis of the DNase I protection data, the boundary of the two regions of protection could be localized to a 46-bp segment of DNA. We decided to address whether this smaller region of 46 bp was sufficient for UAS activity by cloning this region into the pLG⌬178 reporter plasmid and transforming this CTS1(46)-CYC1-lacZ plasmid into a set of isogenic strains bearing null alleles of ACE2 and/or SWI5. The 46-bp fragment in CTS1(46)-CYC1-lacZ directed levels of ␤-galactosidase similar to those seen with the 258-bp fragment (Table 4) . However, the 46-bp fragment provided 38% of wild-type UAS activity in the ace2 mutant, while the 258-bp fragment exhibited only 1% activity. In addition, UAS activity was completely absent in the ace2 swi5 double mutant. We conclude that the 46-bp UAS can be activated by either ACE2 or SWI5, while only ACE2 can activate the 258-bp UAS. This finding suggests that there is a negative regulatory sequence present in the 258-bp fragment that prevents SWI5 activation. When this negative sequence element is removed, as in the case of the 46-bp fragment, then both SWI5 and ACE2 can activate transcription to approximately equal extents.
Identification of a negative element within the CTS1 promoter. We further investigated the role of negative regulation in determining promoter specificity of ACE2 at CTS1. The different responses of the 46-and 258-bp CTS1 promoter fragments to activation by SWI5 suggested that the 258-bp fragment contains a negative sequence element that prevents activation by Swi5p but still allows Ace2p to activate. The 46-bp element, containing the Ace2p binding sites, is roughly centered within the 258-bp CTS1 promoter fragment; we constructed deletions from the 5Ј and 3Ј sides of the 258-bp fragment and cloned these deletion fragments into a lacZ reporter plasmid (Fig. 6) . These constructs were then tested for UAS activity by quantitative ␤-galactosidase assays in a wild-type strain and in an ace2 mutant strain. We expected two types of results. First, a deletion construct, if it contained Ace2p binding sites, would show a level of activity comparable to that of the full-length 258-bp fragment in the wild-type strain. More importantly, a deletion construct lacking the negative sequence element would show increased activation in an ace2 mutant strain over that seen with the full 258-bp UAS. This would indicate that the negative element is removed, suggesting that SWI5 can activate transcription through this deletion construct.
Deletions made from the 5Ј end of the 258-bp promoter fragment are shown in Fig. 6B . Deletion construct Ϫ539 to Ϫ394, in which one of the high-affinity Ace2p binding sites is deleted, has 13% of wild-type UAS activity. Likewise, deletion construct Ϫ520 to Ϫ394, in which the left Ace2p binding site and the first A residue in the conserved ACCAGC core of the right Ace2p binding site are deleted, does not activate transcription at all. The right Ace2p binding site is probably compromised by loss of this residue, since ␤-galactosidase activity was completely abrogated. Thus, deletion of one or both of the Ace2p binding sites severely lowered the normal level of UAS activity in the wild-type strain, consistent with the fact that the 46-bp element containing the sites is an ACE2-dependent UAS. Finally, none of the 5Ј deletion constructs activates transcription in the ace2 strain, suggesting that the negative sequence element is located downstream of the two high-affinity binding sites. Constructs with deletions of the 3Ј region of the 258-bp fragment define a negative regulatory sequence that blocks CTS1 activation by Swi5p (Fig. 6C) . One deletion construct, Ϫ651 to Ϫ418, showed essentially the same regulation as the full-length 258-bp fragment, demonstrating that the negative element sequences are not located between nt Ϫ418 and Ϫ394. When an additional 26 bp were deleted from the promoter fragment in deletion construct Ϫ651 to Ϫ444, the level of activity of the promoter fragment in the ace2 mutant increased to 7% (normalized to the value for the 258-bp fragment in the wild type). Thus, at least part of the negative sequence element has been removed, allowing activation by SWI5. All further deletion constructs allowed increased expression in the ace2 mutant, providing approximately 15 to 20% of wild-type activity. It should be noted that none of the 3Ј deletion constructs ever reached 100% of wild-type activity. This is not surprising because the 46-bp fragment showed only 36% of wild-type activity in an ace2 mutant (Fig. 6A) , indicating the maximum level of activation by SWI5 in an ace2 mutant strain. All of the deletion constructs are transcriptionally silent in an ace2 swi5 double mutant (data not shown), and thus the activation of the deletion constructs in the ace2 mutant is dependent on SWI5. From these results, one can conclude that a negative sequence element must be located between nt Ϫ470 and Ϫ418 within the promoter.
To determine whether this region can negatively regulate a heterologous promoter, we cloned segments of the CTS1 pro- FIG. 6 . A negative regulatory site within the CTS1 promoter. Various CTS1 promoter fragments were cloned upstream of the CYC1 promoter driving expression of the lacZ gene. The CYC1-lacZ reporter lacks a UAS element, and transcriptional activation is dependent on UAS activity in the inserted fragment; activity of the CTS1(258)-CYC1-lacZ reporter is 1,000 times greater than that of the parent pLG⌬178 vector (see Fig. 7B ). The CTS1-CYC1-lacZ constructs were transformed into isogenic strains DY150 (wild type [WT] ) and DY1159 (ace2) and grown under selection to maintain the plasmids, and extracts were prepared for quantitative ␤-galactosidase measurements. The results given are the averages of at least three independent transformants, and the standard error for the ␤-galactosidase assays was under 25%. The values given are expressed as a percentage of the value for the CTS1(258)-CYC1-lacZ construct transformed into the wild-type strain. All promoter constructs were tested in an ace2 swi5 double mutant, and all had Ͻ1% of the activity of the CTS1(258)-CYC1-lacZ reporter in the ACE2 SWI5 strain (data not shown), demonstrating that SWI5 is responsible for the activity seen in ace2 mutants. All constructs in panels A, C, and D were assayed on the same day. In this case, CTS1(258)-CYC1-lacZ produced 2,000 Ϯ 510 U of activity. The constructs in panel B were assayed on a different day, but activities are normalized to that for a CTS1(258)-CYC1-lacZ control in DY150 assayed simultaneously.
VOL. 16, 1996 NEGATIVE REGULATION AT CTS1moter downstream of the CYC1 UAS. CTS1 promoter fragments of 126 and 67 bp, corresponding to nt Ϫ521 to Ϫ394 and Ϫ470 to Ϫ404, respectively, were cloned into plasmid pLG⌬312, which contains the CYC1 promoter driving expression of a lacZ reporter. Placing this region of the CTS1 promoter downstream of the CYC1 UAS causes a 10-to 20-fold drop in lacZ expression (Fig. 7A) . These fragments also repress the CYC1 promoter when inserted in the opposite orientation (data not shown). Insertion of similar-size DNA fragments, such as lexA or MAT␣2 operators (23, 44) or fragments from the HO promoter (unpublished observations), into pLG⌬312 reduces lacZ expression up to twofold. We therefore suggest that the decreased expression is not simply due to increasing the distance between the CYC1 UAS and TATA elements. Thus, the CTS1 negative element can repress expression of a heterologous promoter. Negative regulatory sequence. A genetic screen was undertaken to more closely define the nucleotide residues that constitute the negative sequence element. A site-directed mutagenesis procedure was used to target mutations to the negative regulatory region of the CTS1 promoter as mapped by deletion analysis. We converted plasmid pALTER-1 (Promega), which is designed for oligonucleotide-directed mutagenesis, to a yeast shuttle vector called YCpALTER-URA3 by inserting a yeast URA3 marker, a yeast origin of replication, and a yeast centromere. We then inserted the full-length CTS1 promoter (with an XhoI site between the two Ace2p binding sites) driving expression of the lacZ reporter gene into YC pALTER-URA3 to construct plasmid M2457, which was used as a substrate for site-directed mutagenesis. A doped oligonucleotide, containing on average three mutations per oligonucleotide (18) , was used to construct a plasmid library containing the reporter with mutations in the region from Ϫ454 to Ϫ418, which was then transformed into an ace2 mutant strain. In an ace2 mutant, the parental CTS1-lacZ reporter is expressed at a very low level and yeast colonies remain white on the chromogenic substrate X-Gal because SWI5 fails to activate transcription. On the other hand, mutations in the negative regulatory sequence should allow SWI5 to function at the CTS1 promoter and thus cause the colonies that harbor these mutant plasmids to turn blue in the presence of X-Gal. Of a total of 6,000 colonies screened, 5 colonies exhibited a slightly more blue phenotype in the ace2 strain. All five colonies contained the same two mutations (described below); the five plasmids may not reflect independent mutations, since the library had been amplified in E. coli. Plasmid M2569 containing the mutant promoter was isolated and transformed into an ace2 swi5 double-mutant strain, and no transcriptional activation was seen (data not shown). Thus, we conclude that activation of this mutant promoter requires SWI5.
The 258-bp HpaI-TaqI fragment from plasmid M2569 containing the two point mutations in the CTS1 promoter was cloned into pLG⌬178 for direct comparison with the wild-type 258-bp fragment in the heterologous CTS1 promoter, constructing CTS1(258-mutant)-CYC1-lacZ. As shown in Fig. 6D , the 258-bp fragment containing this negative site mutation showed an increase in transcription in the ace2 mutant strain to 6% of wild-type activity. The activation did not reach the 15 to 20% level seen in the Ϫ651 to Ϫ470 deletion, suggesting that the negative site had not been completely destroyed. Expression from the CTS1(258-mutant)-CYC1-lacZ construct is comparable to that from the Ϫ651 to Ϫ444 deletion construct, which may lack only part of the negative regulatory element. It is possible that additional mutations in another part of the negative regulatory element are required to increase the activity of the CTS1(258-mutant)-CYC1-lacZ construct to 15 to 20%. We suggest that the deletion construct Ϫ651 to Ϫ470 exhibits 16% activity because the second element may have been eliminated. Finally, the activity of the CTS1(258-mutant)-CYC1-lacZ reporter in ace2 swi5 double mutant is less than that seen for the control plasmid pLG⌬178, which lacks a UAS (data not shown). Thus, we conclude that SWI5 is required for the transcriptional activation seen in the CTS1 mutant promoter construct. DNA sequence analysis revealed that two mutations were present in the CTS1 promoter: an A residue at position Ϫ428 changed to a T, and an A residue at position Ϫ426 changed to a G (Fig. 1) . Interestingly, these mutations lie in a 15-bp region, ATGTTGAGTAAACAT (mutated residues are underlined), that demonstrate imperfect dyad symmetry, since the ATGTTNAN sequence appears on opposite strands of the symmetry, with the center of the dyad at the second N residue. DNA sequences with dyad symmetry are often sites that can be recognized by dimeric DNA-binding proteins. Perhaps a specific repressor protein recognizes this sequence and blocks SWI5 activation of CTS1.
The data in Fig. 7A demonstrates that the CTS1 negative element can repress a heterologous UAS. A reporter plasmid identical to M3121 (Fig. 7A, line 3 ) but with the TAAACATto-TTAGCAT substitutions shown in Fig. 1 was constructed, and its expression was assayed in wild-type strains. The plasmid with the substitutions had essentially the same level of expression as M3121, indicating that these mutations do not alleviate repression in the context of this heterologous CYC1 UAS (data not shown). Although the TAAACAT region does not appear to contribute to repression of the heterologous CYC1 UAS, this experiment does not eliminate a role of this sequence element in blocking activation by SWI5.
Negative regulators of CTS1 expression. The promoter analysis suggests that a negative regulatory element present in the CTS1 promoter prevents Swi5p from functioning as a transcriptional activator of CTS1. We reasoned that if there were a specific repressor protein recognizing this promoter element, then a mutation in the gene encoding this repressor should allow Swi5p to activate CTS1 expression in the absence of Ace2p. We performed a genetic screen to look for such a mutation. Our criteria were that the mutation should permit CTS1 to be expressed in an ace2 mutant and that SWI5 must be required for the CTS1 expression.
A CTS1-lacZ reporter was integrated at the LEU2 locus of yeast strains bearing an ace2 gene disruption; this strain displays a white colony color under appropriate assay conditions using X-Gal. This strain was mutagenized with ethyl methanesulfonate, and 28 blue colonies were identified as containing potential mutations in NCE (negative regulator of CTS1 expression) genes. Genetic analysis demonstrated that three mutations were dominant, and these mutations were not characterized further. Seven of the remaining recessive mutations could be sorted into three complementation groups, which we call NCE1, NCE2, and NCE3. We decided to focus on the complementation groups with multiple alleles. Strains carrying nce1, nce2, or nce3 were backcrossed to wild-type strains. Each of the nce mutations segregated 2:2, demonstrating that single mutations are responsible.
All of the nce mutations allow the CTS1 gene to be expressed in the absence of the Ace2p activator. We were interested in identifying mutations which permitted Swi5p to activate CTS1. We therefore constructed ace2 swi5 nce strains carrying the integrated CTS1-lacZ reporter. To quantitate the promoter activity of the CTS1-lacZ reporter, extracts were prepared from log-phase cells and ␤-galactosidase activity assays were performed (Table 5) . Suppression by the nce1 and nce2 mutations is largely SWI5 independent. Less than a twofold difference is seen when the ace2 nce1 SWI5 strain is compared with the ace2 nce1 swi5 strain, and the nce2 strain shows a four-to fivefold difference when SWI5 is present. In contrast, the nce3 mutation shows a substantial dependence on SWI5. The ace2 nce3 SWI5 strain has 14-fold more CTS1-lacZ activity than the ace2 nce3 swi5 strain (compare WY110 [ace2 nce3 SWI5] with WY105 [ace2 nce3 swi5]). To verify that the nce mutations suppressed the ace2 defect in CTS1 transcription at the native CTS1 locus, RNA was prepared from isogenic strains and analyzed by Northern blotting. As shown in Fig. 8 , an ace2 mutation sharply reduces CTS1 mRNA levels (lanes 1 to 4). The nce1, nce2, and nce3 mutations partially suppress the ace2 defect in CTS1 expression (lanes 5, 7, and 9). The nce1 (lanes 5 and 6) and nce2 (lanes 7 and 8) mutations are largely SWI5 independent. The nce3 mutation, however, is strongly SWI5 dependent (lanes 9 and 10). Both the CTS1-lacZ expression studies and the Northern analysis show that ace2 suppression of CTS1 expression by nce3 requires the presence of a functional SWI5 gene.
Two experiments were performed to examine whether the NCE genes act via the negative regulatory element in the CTS1 promoter. First, we used plasmid constructs with CTS1 promoter fragments inserted downstream of the CYC1 UAS. These CTS1 promoter fragments were able to reduce tran- scription from the heterologous CYC1 UAS (Fig. 7A) . The nce1 and nce3 mutations partially relieved the repression imposed by insertion of the CTS1 promoter fragment, suggesting that the NCE1 and NCE3 gene products act via these promoter sequences. We provide two explanations as to why these mutations did not completely abrogate the repression mediated by the inserted fragments. First, these mutations may be missense mutations that still retain partial function. Second, there may be multiple, partially redundant pathways contributing to repression. Next, we determined the effects of the nce mutations on the CTS1(258)-CYC1-lacZ and CTS1(46)-CYC1-lacZ reporters. The negative element is present in the construct with the 258-bp CTS1 fragment but absent from the reporter with the 46-bp fragment, and SWI5 can activate only the CTS1(46)-CYC1-lacZ reporter (Fig. 6) . The activity of each of these promoters was determined in ace2 mutant strains that also had an nce1, nce2, or nce3 mutation (Fig. 7B) . The nce3 mutation permits expression of CTS1 (46)-CYC1-lacZ to 10% of the level seen with the CTS1(258)-CYC1-lacZ reporter. Thus, NCE1 and NCE3 are candidates for specific repressor(s) that bind to the CTS1 promoter and prevent SWI5 from acting as a functional activator.
DISCUSSION
Our results demonstrate that the Ace2p and Swi5p transcriptional activators bind to the same DNA sequences in vitro. Both proteins recognize sites within the CTS1 and HO promoters, and these binding sites show considerable similarity. This result is not surprising, because the DNA-binding domains in the Ace2 and Swi5 zinc finger proteins are nearly identical. Given the fact that both activators can bind to the same sequences in vitro, why does ACE2 not activate HO, nor SWI5 activate CTS1? How do these two transcriptional pathways remain distinct in vivo?
Our data suggest that promoter specificity is achieved by at least two different mechanisms. First, specificity of activation by SWI5 at the HO promoter is due, in part, to combinatorial control. The specificity of binding of Swi5p to the HO promoter is enhanced by an additional protein factor called Pho2p. Our data further support this notion because ACE2 fails to interact with PHO2, as demonstrated by both biochemical and genetic criteria, at either CTS1 or HO. Because there are two adjacent binding sites for Ace2p at the CTS1 promoter, cooperative DNA-binding interactions between two Ace2 proteins could provide a mechanism for promoter specificity, assuming that Swi5p was unable to bind cooperatively at these sites. However, in vitro binding experiments have failed to detect any cooperativity in Ace2p binding at the CTS1 promoter (data not shown and reference 13). It is possible that an as yet unidentified factor promotes cooperative binding at CTS1 by Ace2p and thus enhances CTS1 promoter specificity for Ace2p but not for Swi5p.
Second, our results illustrate the importance of negative regulation as a mechanism for determining promoter specificity via the Ace2p and Swi5p activators. Deletion or mutation of sequences in a cis-acting negative regulatory region within the CTS1 promoter allow SWI5 to partially function at CTS1, a gene that SWI5 does not normally activate. Likewise, a mutation in the NCE3 gene results in SWI5-dependent up-regulation of CTS1 expression in the absence of the Ace2p activator. These results, taken together, suggest that there is a protein factor capable of mediating its negative effects through the CTS1 negative regulatory site. Whether an NCE gene encodes this factor, and whether it interacts through the negative regulatory site, remains to be determined.
Given the observation that negative regulation occurs at CTS1, it is notable that negative regulation also plays a role in the specific activation of the HO gene by Swi5p. Our data indicate that negative regulation plays a role in preventing ACE2 from activating HO (39) . SIN5 was identified by a suppressor mutation that allows HO expression in the absence of the Swi5p activator, and thus SIN5 is a negative regulator of HO. Importantly, the sin5 mutation was shown to be unable to suppress the swi5 defect in HO expression when the strain also lacked Ace2p. One interpretation of this result is that the normal function of SIN5 is to prevent ACE2 from activating HO transcription. Thus, the SIN5 gene functions at HO in a fashion reciprocal to that seen for NCE3 at CTS1.
Negative regulation could contribute to promoter specificity of Ace2p by multiple mechanisms (12, 19, 28, 33) . First, a negative regulatory protein could compete with the activator for its binding site. In this case, the negative regulatory protein would selectively interfere with Swi5p binding. Given that the negative regulatory region of the CTS1 promoter is situated 80 to 90 bp downstream from the Ace2p binding sites, we feel that it is unlikely that such a protein would prevent Ace2p or Swi5p from binding, although this possibility still exists. Second, negative regulation could contribute to promoter specificity by interfering with the abundance, level of activity, or cell cycleregulated expression of each activator. Similarly, the DNA binding of either activator could be blocked via sequestration by interaction with a particular negative regulator. We think that both of these mechanisms are unlikely, given the facts that ACE2 and SWI5 show identical patterns of cell cycle-regulated mRNA expression and nuclear localization and that CTS1 and HO show identical cell cycle regulation (14) . However, it is possible that the nce3 mutation affects the stability, localization, or abundance of Swi5p and thus allows Swi5p to overcome the negative regulation at CTS1. Finally, negative regulation could be achieved by interfering with the DNA-bound activator, analogous to Gal80p, which binds to Gal4p and inhibits the Gal4p activation domain. For example, a CTS1-specific repressor could interfere with the activity of the Swi5p activator at the CTS1 promoter but not with the Ace2p activator. It is not entirely clear how such a regulator would achieve this selective interference at CTS1, because it should similarly interfere with activation of HO by Swi5p. As described below, we believe that the negative regulation occurs at the promoter, thus providing promoter specificity.
There are a number of observations supporting the role of negative regulation in determining promoter specificity of Ace2p and Swi5p. First, point mutations or deletions of the negative regulatory element within the CTS1 promoter allow SWI5 to partially activate the CTS1 promoter. Second, an nce3 mutation also allows the CTS1 gene to be activated by SWI5. These results are consistent with, but do not prove, the existence of a DNA-binding negative regulator that binds to the CTS1 promoter and prevents Swi5p activator function. At present, we cannot distinguish between a model in which the negative regulator blocks Swi5p binding and one in which the negative regulator simply interferes with the activation domain of Swi5p. Additionally, we have demonstrated that overexpression of either ACE2 or SWI5 allows inappropriate activation of the opposite target gene. This observation is consistent with the negative regulation model, as increased abundance of the Swi5p activator may overcome the negative regulator simply by mass action. Not surprisingly, CTS1 or HO expression never achieves wild-type levels in response to overexpression of the incorrect activator. Negative regulation has recently been shown to play an important role in the tissue specificity of activation of mammalian genes (9, 45) . Analogous to our situation with Ace2p and Swi5p, the two basic helix-loop-helix proteins MyoD and E12 can recognize the same DNA-binding sites in vitro (46) . MyoD is responsible for activating myogenic genes, whereas E12 is responsible for activating the immunoglobulin heavychain enhancer. Although both activators can bind to the same sequences in vitro, one reason that MyoD does not activate the nonmuscle enhancers is that these enhancers contain cis-acting repression elements (45) . It appears, analogous to our situation, that these cis-acting elements prevent MyoD from functioning as an activator. Weintraub et al. (45) also propose the existence of a specific repressor protein, but they note that other mechanisms of negative regulation could also be responsible. Chong et al. (9) identified a zinc finger DNA-binding protein, called REST, that acts to repress gene expression in a tissue-specific manner. Thus, negative regulation is emerging as an important mechanism for determining promoter specificity of transcriptional activators.
The question then arises as to why ACE2 and SWI5 did not evolve to recognize unique DNA sequences, or alternatively, why does ACE2 (or SWI5) not activate both the CTS1 and HO genes in vivo? ACE2 and SWI5 can be considered genetically redundant in that they bind to the same DNA sequences in vitro and show a high degree of homology. At this point, the selective value of maintaining both genes is not directly apparent. Thomas (42) discussed several mechanisms by which selection could act to maintain this genetic redundancy. One potential mechanism that applies is the selection of divergent function. Thus, although both genes evolved divergently (i.e., ACE2 for CTS1 expression and SWI5 for HO expression), if the two activators have overlapping but nonidentical functions, selective pressure will maintain their redundant regions. Our preliminary observations suggest that either ACE2 or SWI5 is required for the transcriptional activation of other yeast genes (unpublished observations), and thus these two activators are redundant for this function. We propose that SWI5 and ACE2 arose by duplication of a single precursor gene followed by divergence. At the same time, selective pressure acted to maintain the very similar DNA-binding domains required for the activation of genes that can respond to either ACE2 or SWI5. Logically, the regions of divergence between Ace2p and Swi5p must be responsible for the specificity in activation of either CTS1 or HO. It is clear from domain-swapping experiments with chimeric activators that the specificity domain lies outside the DNA-binding domains of Ace2p and Swi5p (14) . In fact, we have been able to construct a chimeric protein capable of activating both CTS1 and HO genes (28a), and we would suggest that this hybrid protein contains the specificity domains from both Ace2p and Swi5p.
In this report, we have focused on the role of negative regulation in determining the promoter specificities of transcriptional activators. Clearly, there are many examples of situations in which combinatorial control participates in promoter selectivity of DNA-binding proteins. For example, Oct-1 and Oct-2 homeodomain proteins recognize the same cis-regulatory DNA sequences in vitro, but association with other proteins confers a new DNA-binding specificity upon Oct-1, leading to recognition of specific promoters (11) . The MAT␣2 protein can bind DNA cooperatively with different partner proteins, and thus it can recognize distinct sites and regulate different sets of genes (15, 22) . At the HO promoter, Swi5p binds cooperatively with the Pho2 homeodomain protein (4, 5) whereas Ace2p cannot, and this combinatorial control probably contributes to the HO promoter specificity of Swi5p. On the basis of the presence of two Ace2p binding sites at the CTS1 promoter, we proposed that two Ace2p molecules (but not Swi5p) may bind cooperatively with an additional protein and thus contribute to promoter specificity. Finally, we note that the negative regulation and combinatorial control models are not mutually exclusive, and thus both mechanisms can contribute to promoter specificity in vivo.
Presumably, the specificity domains of each transcription factor are regions involved in protein-protein interactions. We believe that the role of these domains is to increase the specificity of activation in two ways: first, at the level of DNA binding through the cooperative interaction with a second protein, and second, by overcoming the repressive influences of specific negative regulators. Combining these two mechanisms increases the likelihood that activation by the inappropriate transcription factor does not occur. Clearly, a detailed analysis of the regions involved will be required to understand the promoter specificity of transcriptional activation of Ace2p and Swi5p.
